

Express Mail Label No.

Dated: 12-12-03

Docket No.: 01252/1200687-US1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Nadji Sourena

Application No.: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Filed: Concurrently Herewith

Art Unit: N/A

For: PROCESS FOR THE PRODUCTION OF
PENTOSTATIN AGLYCON AND
PENTOSTATIN

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, attached hereto is a copy of Form PTO/SB/08 and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO/SB/08) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form Form PTO/SB/08 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application. This Information Disclosure Statement accompanies the new patent application submitted herewith.

A copy of each document on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is “prior art” for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: December 12, 2003

Respectfully submitted,

By Jason C. Chumney
 Jason C. Chumney
 Registration No.: 54,781
 DARBY & DARBY P.C.
 P.O. Box 5257
 New York, New York 10150-5257
 (212) 527-7700
 (212) 753-6237 (Fax)
 Attorneys/Agents For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Nadji Sourena
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	01252/1200687-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		J. Org. Chem, Eunice Chan, et al. "Total Synthesis of (8R)-3-(2-Deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d]1,3]diazepin-8-ol (Pentostatin), the Potent Inhibitor of Adenosine Deaminase ^{1a} , 47, 3457-3464, 1982.	
		J. Org. Chem, Thien Van Truong et al, "Chirospecific Synthesis of the Tetrahydroimidazodiazepinol Aglycon of Pentostatin and Its Analogues", 58, 6090-6096, 1993.	
		Submitted by Seiki Saito, et al., "Diethyl (2S,3R)-2-(N-tert-Butoxycarbonyl)Amino-3-Hydroxysuccinate", Vol. 73, 1995.	
		American Chemical Society, David C. Baker, "A Total Synthesis of Pentostatin, ¹ the Potent Inhibitor of Adenosine Deaminase", 0002-7863/79/1501-6127, 1979.	
		J. Heterocyclic Chem, D.C. Baker et al., "Studies Related to the Total Synthesis of Pentostatin. Approaches to the Synthesis of (8R)-3,6,7,8-Tetrahydroimidazo[4,5-d][diazepin-8-d and N-3 Alkyl Congeners (1a)", Vol 20, 629-634, 1983.	
		The Journal of Antibiotics, H.D. Hollis Showalter, et al., "Improved Production of Pentostatin and Identification of Fermentation Cometabolites", Vo1. 45, No. 12, 1914-1918, 1982.	
		Drugs of the Future, "Antihypertensive Calcium Channel Blocker, Vol. 15, No. 7, 1990.	
		J. Am Chem. Soc., Kazuhiro Haraguchi, et al. "Synthesis and Characterization of Oligodeoxynucleotides Containing Formamidopyrimidine Lesions and Nonhydrolyzable Analogues", 124, 3263-3269, 2002.	
		American Chemical Society, Brett C. Bookser, et al., "AMP Deaminase Inhibitors.2. Initial Discovery of a Non-Nucleotide Transition-State Inhibitor Series ¹ ", Vol. 43, No. 8, 1495-1507, 2000.	
		J. Am. Chem. Soc., Mark D. Erion, et al., "Discovery of AMP Mimetics that Exhibit High Inhibitory Potency and Specificity for AMP Deaminase" 121, 308-319, 1999.	
		Nucleosides & Nucleotides, H. Jeanette Thomas, et al., "The Synthesis of Coformycin From 5-Amino-1-β-D-Ribofuranosylimidazole-4-Carboxamide", 5(4) 431-439, 1986.	
		Nucleosides & Nucleotides, Mikyung Hong, et al. "Irreversible, Tight-Binding Inhibition of Adenosine Deaminase By Coformycins: Inhibitor Structural Features That Contribute to the Mode of Enzyme Inhibition", 16(7-9), 1053-1057, 1997.	

{W:012 1 521200	Date Considered	
--------------------	--------------------	--